Pharmacokinetics of Sertindole and its Metabolite Dehydrosertindole in Rats and Characterization of their Comparative Pharmacodynamics based on In Vivo D2 Receptor Occupancy and Behavioural Conditioned Avoidance Response

被引:10
作者
Bundgaard, Christoffer [1 ]
Larsen, Frank [1 ]
Kreilgaard, Mads [1 ]
Brennum, Lise T. [1 ]
Olsen, Christina Kurre [1 ]
机构
[1] H Lundbeck AS R&D, DK-2500 Copenhagen, Denmark
关键词
conditioned avoidance response; pharmacokinetics; pharmacodynamics; occupancy; sertindole; DOPAMINE-RECEPTORS; ANTIPSYCHOTICS; SCHIZOPHRENIA; VOLUNTEERS; ANTAGONIST; CLOZAPINE; MIDAZOLAM; SUBTYPES; AGONIST; BINDING;
D O I
10.1002/bdd.656
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objectives of this study were to characterize the pharmacokinetics of sertindole and its active metabolite dehydrosertindole in rats and to evaluate the central modulatory and behavioural pharmacodynamics including a competitive interaction model between the compounds. Following oral administration of sertindole or dehydrosertindole, the plasma concentration-time courses were determined in conjunction with striatal dopamine D-2 receptor binding. In addition, the behavioural effects were recorded in the conditioned avoidance response (CAR) paradigm. A one-compartment model with Michaelis-Menten elimination best described the pharmacokinetics of sertindole. Formation of dehydrosertindole was incorporated into the pharmacokinetic model and exhibited first-order elimination. PK/PD modelling after administration of dehydrosertindole resulted in potency estimates of 165 and 424 ng/ml for D-2-occupancy (Kd) and CAR measurements (EC50), respectively. The pharmacokinetics of the parent-metabolite system was integrated into a competitive pharmacodynamic E-max model in order to quantitate the potency of sertindole with the pharmacodynamic parameters of the metabolite taken into account. Based on this approach, effect compartment concentrations of sertindole needed to attain 50% occupancy and half-maximal effect in the CAR paradigm were 133 and 338 ng/ml, respectively. The corresponding potency-estimates obtained after conventional modelling of the sertindole data without accounting for the metabolite amounted to 102 and 345 ng/ml. Based on competitive PK/PD analysis of the parent-metabolite interaction, the relative contribution of dehydrosertindole to the overall pharmacological effect after sertindole administration in rats appeared to be of minor significance. This could mainly be ascribed to the relatively low extent of bioconversion of sertindole into dehydrosertindole in this species. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:209 / 220
页数:12
相关论文
共 34 条
[1]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[2]   Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation [J].
Chien, JY ;
Friedrich, S ;
Heathman, MA ;
de Alwis, DP ;
Sinha, V .
AAPS JOURNAL, 2005, 7 (03) :E544-E559
[3]   The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model [J].
Cox, EH ;
Langemeijer, MWE ;
Gubbens-Stibbe, JM ;
Muir, KT ;
Danhof, M .
ANESTHESIOLOGY, 1999, 90 (02) :535-544
[4]   Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment [J].
Didriksen, Michael ;
Kreilgaard, Mads ;
Arnt, Jorn .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 542 (1-3) :108-115
[5]  
FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
[6]   Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment [J].
Hietala, J ;
Kuoppamäki, M ;
Majasuo, H ;
Pälvimäki, EP ;
Laakso, A ;
Syvälahti, E .
PSYCHOPHARMACOLOGY, 2001, 157 (02) :180-187
[7]   KINETICS OF PHARMACOLOGIC RESPONSE [J].
HOLFORD, NHG ;
SHEINER, LB .
PHARMACOLOGY & THERAPEUTICS, 1982, 16 (02) :143-166
[8]   Dynamin and Rab5 regulate GRK2-dependent internalization of dopamine D2 receptors [J].
Iwata, K ;
Ito, K ;
Fukuzaki, A ;
Inaki, K ;
Haga, T .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 263 (02) :596-602
[9]   Relationship between dopamine D2 occupancy, clinical response, and side effects:: A double-blind PET study of first-episode schizophrenia [J].
Kapur, S ;
Zipursky, R ;
Jones, C ;
Remington, G ;
Houle, S .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (04) :514-520
[10]   Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy [J].
Kapur, S ;
Vanderspek, SC ;
Brownlee, BA ;
Nobrega, JN .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02) :625-631